A survey of prospective, controlled clinical trials of gentamicin, tobramycin, amikacin, and netilmicin.
L A Cone
Abstract
L A Cone
Abstract
Data from 24 prospective, controlled clinical studies of the aminoglycosides gentamicin, tobramycin, amikacin, and netilmicin are reviewed. According to these findings, netilmicin is the safest and most effective of the four types (P less than 0.01, both comparisons), and gentamicin is more effective than tobramycin (P less than 0.05) and less ototoxic than amikacin (P less than 0.05).
OpenAlex reports 32 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Data from 24 prospective, controlled clinical studies of the aminoglycosides gentamicin, tobramycin, amikacin, and netilmicin are reviewed. According to these findings, netilmicin is the safest and most effective of the four types (P less than 0.01, both comparisons), and gentamicin is more effective than tobramycin (P less than 0.05) and less ototoxic than amikacin (P less than 0.05).
Key concepts: Netilmicin, Tobramycin, Amikacin, Medicine, Gentamicin, Aminoglycoside, Antibiotics, Microbiology